Search Results - "Lavasani, Sayeh"

Locoregional Treatment for Early-Stage Breast Cancer: Current Status and Future Perspectives by Lavasani, Sayeh, Healy, Erin, Kansal, Kari

“…Background: The locoregional recurrence of breast cancer has been reduced due to the multidisciplinary approach of breast surgery, systemic therapy and…”
Get full text

Phase 2 prospective open label study of neoadjuvant nab‐paclitaxel, trastuzumab, and pertuzumab in patients with HER2‐positive primary breast cancer by Lavasani, Sayeh M., Somlo, George, Yost, Susan E., Frankel, Paul H., Ruel, Christopher, Cui, Yujie, Murga, Mireya, Tang, Aileen, Martinez, Norma, Kruper, Laura, Tumyan, Lusine, Schmolze, Daniel, Yeon, Christina, Yuan, Yuan, Waisman, James R., Mortimer, Joanne

“…Background The objective of this study was to evaluate the safety and efficacy of nab‐paclitaxel, trastuzumab, and pertuzumab as neoadjuvant therapy (NAT) in…”
Get full text

Effect of depression before breast cancer diagnosis on mortality among postmenopausal women by Liang, Xiaoyun, Margolis, Karen L., Hendryx, Michael, Reeves, Katherine, Wassertheil‐Smoller, Sylvia, Weitlauf, Julie, Danhauer, Suzanne C., Chlebowski, Rowan T., Caan, Bette, Qi, Lihong, Lane, Dorothy, Lavasani, Sayeh, Luo, Juhua

“…BACKGROUND Few previous studies investigating depression before the diagnosis of breast cancer and breast cancer–specific mortality have examined depression…”
Get full text

UGT1A128 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan by Wong, Megan H., Jones, Veronica C., Yu, Wai, Bosserman, Linda D., Lavasani, Sayeh M., Patel, Niki, Sedrak, Mina S., Stewart, Daphne B., Waisman, James R., Yuan, Yuan, Mortimer, Joanne E.

“…Background Sacituzumab govitecan (sacituzumab) emerged as an important agent in metastatic and locally recurrent HER2‐negative breast cancer treatment. UGT1A1…”
Get full text

Statins and breast cancer stage and mortality in the Women's Health Initiative by Desai, Pinkal, Lehman, Amy, Chlebowski, Rowan T., Kwan, Marilyn L., Arun, Monica, Manson, JoAnn E., Lavasani, Sayeh, Wasswertheil-Smoller, Sylvia, Sarto, Gloria E., LeBoff, Meryl, Cauley, Jane, Cote, Michele, Beebe-Dimmer, Jennifer, Jay, Allison, Simon, Michael S.

“…Purpose: To evaluate the association between statins and breast cancer stage and mortality in the Women's Health Initiative. Methods: The study population…”
Get full text

HER2-targeted antibody–drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia by Rainone, Michael, Behrendt, Carolyn E., Kasparian, Saro, Nguyen, Tina, Sedrak, Mina S., Lavasani, Sayeh, Stewart, Daphne B., Yuan, Yuan, Mortimer, Joanne E., Waisman, James R., Patel, Niki, Pullarkat, Vinod

“…Background Thrombocytopenia is a common adverse event on HER2-targeted therapies, fam-trastuzumab deruxtecan (T-DXd) and ado-trastuzumab emtansine (T-DM1). A…”
Get full text

Use of Calcium Channel Blockers and Breast Cancer Risk in the Women's Health Initiative by Brasky, Theodore M, Krok-Schoen, Jessica L, Liu, Jingmin, Chlebowski, Rowan T, Freudenheim, Jo L, Lavasani, Sayeh, Margolis, Karen L, Qi, Lihong, Reding, Kerryn W, Shields, Peter G, Simon, Michael S, Wactawski-Wende, Jean, Wang, Ange, Womack, Catherine, Manson, JoAnn E

“…Use of calcium channel blockers (CCBs) has been associated with increased risk of breast cancer in some, but not all, studies. Differences in reported…”
Get full text

Use of HER2-Directed Therapy in Metastatic Breast Cancer and How Community Physicians Collaborate to Improve Care by Mortimer, Joanne E, Kruper, Laura, Cianfrocca, Mary, Lavasani, Sayeh, Liu, Sariah, Tank-Patel, Niki, Sedrak, Mina, Smith, Wade, Stewart, Daphne, Waisman, James, Yeon, Christina, Wang, Tina, Yuan, Yuan

“…The development of new HER2-directed therapies has resulted in a significant prolongation of survival for women with metastatic HER2-positive breast cancer…”
Get full text

Surviving Burnout as an Oncologist by Lavasani, Sayeh

“…Purpose of Review The aim of this review is defining burnout in medical oncologists, analyzing the causes, and evaluating both individual and institutional…”
Get full text

Hyperglycemia and Glycemic Variability Associated with Glucocorticoids in Women without Pre-Existing Diabetes Undergoing Neoadjuvant or Adjuvant Taxane Chemotherapy for Early-Stage Breast Cancer by Mahin, Dana, Lavasani, Sayeh Moazami, Cristobal, Leon, Tank Patel, Niki, Sedrak, Mina, Stewart, Daphne, Waisman, James, Yuan, Yuan, Yu, Wai, Samoa, Raynald, Ruel, Nora, Yost, Susan E, Lee, Hayley, Kil, Sung Hee, Mortimer, Joanne E

“…Glucocorticoids, which are administered with chemotherapy, cause hyperglycemia. Glycemic variability among breast cancer patients without diabetes is not well…”
Get full text

Estrogen therapy and breast cancer in randomized clinical trials: a narrative review by Pan, Kathy, Lavasani, Sayeh, Aragaki, Aaron K., Chlebowski, Rowan T.

Get full text

Estrogen therapy and breast cancer in randomized clinical trials: a narrative review by Pan, Kathy, Lavasani, Sayeh, Aragaki, Aaron K., Chlebowski, Rowan T.

“…In the Women's Health Initiative (WHI) randomized trial with 10,739 postmenopausal women with prior hysterectomy, conjugated equine estrogen (CEE) alone…”
Get full text

Factors associated with response to neoadjuvant chemotherapy and immune checkpoint inhibition in triple-negative breast cancer by LeVee, Alexis, Wong, Megan, Flores, Sarah, Ruel, Nora H., Lavasani, Sayeh Moazami, Patel, Niki, Sedrak, Mina S., Stewart, Daphne B., Waisman, James Ross, Yuan, Yuan, Mortimer, Joanne E.

“…e12593 Background: Immune checkpoint inhibition with pembrolizumab plus neoadjuvant chemotherapy is now the standard-of-care in patients with high-risk…”
Get full text

Incidence of diabetes and prediabetes unmasked by dexamethasone in women undergoing (neo) adjuvant taxane therapy by Mahinbakht, Dana, Lavasani, Sayeh Moazami, Yu, Wai (Kim), Samoa, Raynald, Ruel, Nora, Mortimer, Joanne E.

“…Abstract only e12526 Background: Women with early stage breast cancer receive premedication with dexamethasone prior to administration of paclitaxel and…”
Get full text

Abstract P4-11-12: Integrating the patient and partner distress and perceptions about prognosis in women with metastatic breast cancer guides the medical oncology consultation by Mortimer, Joanne, Waisman, James, Yuan, Lavasani, Sayeh, Stewart, Daphne, Sedrak, Mina, Patel, Niki, Bitz, Courtney, Clark, Karen, Razavi, Marianne, Loscalzo, Matthew J

“…Abstract Methods: Women with metastatic breast cancer and their partners completed couples’ tailored biopsychosocial screening and alignment in perception of…”
Get full text

Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer by Ge, Xuan, Behrendt, Carolyn E, Yost, Susan E, Patel, Niki, Samoa, Raynald, Stewart, Daphne, Sedrak, Mina, Lavasani, Sayeh, Waisman, James, Yuan, Yuan, Mortimer, Joanne

“…Abstract Background Hyperglycemia is recognized as a common adverse event for patients receiving alpelisib but has been little studied outside of clinical…”
Get full text

UGT1A1 28/28 genotype and risk of toxicity and disease progression in breast cancer patients treated with sacituzumab govitecan-hziy by Wong, Megan, Behrendt, Carolyn E., Yu, Wai (Kim), Bosserman, Linda D., Lavasani, Sayeh Moazami, Patel, Niki, Sedrak, Mina S., Stewart, Daphne B., Waisman, James Ross, Yuan, Yuan, Mortimer, Joanne E.

“…1033 Background: In metastatic and locally recurrent breast cancer the antibody drug conjugate, sacituzumab govitecan-hziy (SG), is approved as a second-line…”
Get full text

Estrogen Plus Progestin and Colorectal Cancer: Long-Term Findings From the Women's Health Initiative Randomized Clinical Trial by Chlebowski, Rowan T, Aragaki, Aaron K, Pan, Kathy, Luo, Juhua, Rohan, Thomas E, Johnson, Karen C, Wactawski-Wende, Jean, Jung, Su Yon, Xiao, Qian, Lavasani, Sayeh, Manson, JoAnn E, Simon, Michael S

“…JCO We report long-term colorectal cancer findings from the Women's Health Initiative trial where 16,608 postmenopausal women with a uterus were randomly…”
Get full text

Predicting hyperglycemia among patients receiving alpelisib plus fulvestrant for metastatic breast cancer by Ge, Xuan, Behrendt, Carolyn E., Yost, Susan Elaine, Patel, Niki, Samoa, Raynald, Stewart, Daphne B., Sedrak, Mina S., Lavasani, Sayeh Moazami, Waisman, James Ross, Yuan, Yuan, Mortimer, Joanne E.

“…1060 Background: Although hyperglycemia is recognized as a common adverse event (AE) on alpelisib (ALP), this AE has been little studied outside clinical…”
Get full text

HER2-targeted immunoconjugates for breast cancer: Ancestry and dose adjustment for thrombocytopenia by Rainone, Michael, Behrendt, Carolyn E., Kasparian, Saro, Nguyen, Tina, Mortimer, Joanne E., Yuan, Yuan, Waisman, James Ross, Stewart, Daphne B., Lavasani, Sayeh Moazami, Sedrak, Mina S., Patel, Niki, Pullarkat, Vinod A.

“…1048 Background: Thrombocytopenia (TCP) is a common toxicity of HER2-targeted agents, trastuzumab emtansine (TDM1) and trastuzumab deruxtecan (TDXd). A high…”
Get full text